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Neurogenesis is altered in neurodegenerative disorders, partly regulated by inflammatory factors. We
have investigated whether microglia, the innate immune brain cells, regulate hippocampal neurogenesis
in neurodegeneration. Using the ME7 model of prion disease we applied gain- or loss-of CSF1R function,
as means to stimulate or inhibit microglial proliferation, respectively, to dissect the contribution of these
cells to neurogenesis. We found that increased hippocampal neurogenesis correlates with the expansion
of the microglia population. The selective inhibition of microglial proliferation caused a reduction in
neurogenesis and a restoration of normal neuronal differentiation, supporting a pro-neurogenic role
for microglia. Using a gene screening strategy, we identified TGFb as a molecule controlling the microglial
pro-neurogenic response in chronic neurodegeneration, supported by loss-of-function mechanistic
experiments.
By the selective targeting of microglial proliferation we have been able to uncover a pro-neurogenic
role for microglia in chronic neurodegeneration, suggesting promising therapeutic targets to normalise
the neurogenic niche during neurodegeneration.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction an excellent model to study some of the mechanisms involved inMammalian adult hippocampal neurogenesis is an active pro-
cess in the healthy brain and is modulated in response to brain
injury and neurodegeneration (Parent, 2003). However, the regula-
tion of hippocampal neurogenesis in chronic neurodegenerative
diseases is unclear, as the animal models for multi-factorial dis-
eases such as Alzheimer’s disease (AD) often fail to reproduce the
entire pathology, adding more variability to an already heteroge-
neous landscape (Kokjohn and Roher, 2009). Thus, there is a clear
need for a better understanding of neurogenesis during chronic
neurodegeneration, arising from experimental models that recapit-
ulate the human pathophysiology. In this line, models of prion dis-
ease have been used to mimic chronic neurodegeneration, as they
are reproducible and recapitulate phenotypes present in several
neurodegenerative diseases, such as microglial activation, mis-
folded protein deposition and neurodegeneration, making themneurodegeneration and neurogenesis (Gomez-Nicola and Perry,
2014a; Gomez-Nicola et al., 2014c). Although models of prion dis-
ease differ from models of AD-like pathology in their duration
(5 months vs. 6–18 months), severity (models of AD-like pathology
show no neuronal death while prion disease has extensive neu-
rodegeneration) and induction (models of prion disease are induci-
ble vs. AD-like pathology are transgenic), they better resemble the
pathophysiology of human chronic neurodegeneration. We
recently described an aberrant over-activation of the neurogenic
cascade during chronic neurodegeneration in models of prion dis-
ease, which led to an effective compensatory replacement of
degenerating granule cells, and correlates with findings from
human post-mortem tissue (Gomez-Nicola et al., 2014c). However,
the molecular determinants of this process are still to be
unravelled.
A key component in the interplay between neurodegeneration
and neurogenesis is inflammation (Amor and Woodroofe, 2014).
Inflammation is a common factor in many neurodegenerative
diseases, triggered by neuronal damage, protein misfolding and
amyloid deposition. Although microglia are the main inflammatory
cells in the CNS, their exact role in regulating neurogenesis remains
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ever, neuroinflammation has been shown to alter neurogenesis in
various conditions. By interacting with neuronal precursors, micro-
glia can increase neurogenesis after environmental enrichment or
decrease it in response to ageing (Kohman et al., 2013; Ziv et al.,
2006). The impact of microglia on neurogenesis seems to depend
on their activation profile, with pro-inflammatory states impairing
neurogenesis and anti-inflammatory states supporting it (Butovsky
et al., 2006; Kohman et al., 2013). Microglial activation following
LPS decreases neuronal survival (Ekdahl et al., 2003; Monje et al.,
2003; Valero et al., 2014) and inhibits neural stem cells (NSCs) pro-
liferation (Fujioka and Akema, 2010) and affects cell integration
into existing neural circuits (Jakubs et al., 2008). On the other hand,
activation of microglia with an anti-inflammatory molecule, such
as TGFb, increases NSCs proliferation (Mathieu et al., 2010). The
neurogenic impairment seen after LPS injection can be rescued
by treatment with minocycline or anti-inflammatory drugs, sug-
gesting a microglia-dependent mechanism (Ekdahl et al., 2003;
Monje et al., 2003). Together, these studies suggest a key role for
microglia in regulating neurogenesis in disease. A better under-
standing of how neuroinflammation contributes to neurogenesis
is therefore crucial to better discern the self-repairing potential
of the brain (Miller and Gomez-Nicola, 2014).
In our previous studies, we identified the crucial role of colony-
stimulating factor 1 receptor (CSF1R) for the expansion and inflam-
matory activation of the microglial population in prion disease
(Gomez-Nicola et al., 2013, 2014b). The activation of CSF1R by its
ligands CSF1 and IL-34 is key for the maintenance of microglial
proliferation and survival in both health and disease
(Gomez-Nicola and Perry, 2014a). Inhibition of CSF1R activation
with a selective tyrosine kinase inhibitor (GW2580) is an effective
way to arrest the expansion of microglia and to drive a shift
towards an anti-inflammatory profile (Gomez-Nicola et al., 2013),
providing us with a valuable tool to target the contribution of
microglia to neurogenesis.
In summary, the role of microglia in the regulation of neuroge-
nesis in chronic neurodegeneration needs to be explored in detail.
Experimental models of prion disease are predictable systems to
study the interaction of microglia and neurogenesis, as previously
described by our group (Gomez-Nicola et al., 2013, 2014c). In par-
ticular, we hypothesise that the control of microglial numbers, by
means of up- or down-regulating their proliferation (gain- or
loss-of-activity of CSF1R), will help dissecting the contribution of
these cells to hippocampal neurogenesis in prion disease, and
further identify any molecular determinants of this response. Our
findings support a pro-neurogenic role of microglia in prion dis-
ease and highlight the crucial role of TGFb in regulating this pro-
cess. Our results link neuroinflammation and neurogenesis
during chronic neurodegeneration, and open new avenues to
explore the therapeutic value of immunomodulatory strategies to
control the self-repairing potential of the brain.2. Materials and methods
2.1. Animal tissue and ethical licence
C57BL/6J (Harlan) and c-fms-EGFP mice (macgreen) (Sasmono
et al., 2003) were bred and maintained at the University of
Southampton. Mice expressing EGFP under the promoter of c-fms
(CSF1R) are characterised by the expression of green fluorescence
in microglial cells and other macrophages. Male or female mice
were housed in groups of 4–10, under a 12-h light/12-h dark cycle
at 21 C, with food and water ad libitum. Prion disease was induced
under anaesthesia with a ketamine/rompun mixture (85 and
13 mg/kg respectively), and injection of 1 ll of either ME7-derived (ME7-animals; model of prion disease; 10% w/v) or normal
brain homogenate (NBH-animals), injected stereotaxically and
bilaterally in the brain at the coordinates from bregma: anteropos-
terior, 2.0 mm; lateral, 1.7 mm; depth, 1.6 mm. All procedures
were performed in accordance with U.K. Home Office licensing.
2.2. Gain/loss of activity of CSF1R
For gain of function experiments, NBH (control) and ME7
(prion) macgreen mice were treated at 12 weeks post-injection
with 50 ng of recombinant murine CSF1 (Merck Chemicals;
n = 4), murine IL34 (R&D Systems; n = 4) or saline (vehicle; n = 4)
by stereotactic injection in the dorsal hippocampus (CA1 field;
anteroposterior, 2.0 mm; lateral, 1.7 mm; depth, 1.6 mm) with
a Hamilton syringe. Mice received 5 injections of i.p. BrdU
(Sigma–Aldrich; 7.5 mg/ml, 0.1 ml/10 g weight in sterile saline),
before the end of the experiment (+1 week), as previously
described (Gomez-Nicola et al., 2013).
Inhibition of the tyrosine kinase activity of CSF1R was achieved
by the administration of GW2580, as previously described
(Gomez-Nicola et al., 2013). GW2580 (LC Laboratories) was sus-
pended in 0.5% hydroxypropylmethylcellulose and 0.1% Tween
80 and was dosed by oral gavage, using gavaging needles, at
0.2 ml per mouse (75 mg/kg), daily for 4 consecutive weeks (from
14th to 18th week post-injection), to NBH and ME7 mice (n = 8),
using the vehicle as control (n = 8). Mice weight was monitored
during the experiment. Mice received 2 daily injections of i.p. BrdU
(Sigma–Aldrich; 7.5 mg/ml, 0.1 ml/10 g weight in sterile saline),
before the end of the experiment (18th week).
2.3. Immunohistochemistry
Mice perfusion, tissue processing and immunohistochemical
analysis were carried out as previously described (Gomez-Nicola
et al., 2013, 2014c). The general immunohistochemistry protocol
was modified for the detection of BrdU, adding a DNA denaturation
step with 2 N HCl (30 min, 37C) before blocking. The following pri-
mary antibodies were used: goat anti-DCX (Doublecortin; Santa
Cruz Biotechnologies), mouse anti-BrdU (DSHB), mouse anti-
NeuN (Millipore), rabbit anti-GFAP (Glial Fibrillary Acidic Protein;
Dako) and rabbit anti-TGFb (Abcam). Following primary antibody
incubation, the sections were washed and incubated with the
appropriate biotinylated secondary antibody (Vector Labs) fol-
lowed by ABC amplification (Vector Labs), and/or with the appro-
priate Alexa 405, 488 or 568 conjugated secondary antibody or
streptavidin (Molecular Probes). For co-labelling in brightfield, fol-
lowing primary antibody, sections were incubated with a biotiny-
lated secondary antibody (Vector Labs) followed by ABC
amplification (Vector Labs), and the ImmPRESS-AP (alkaline phos-
phatase) Polymer Detection Kit. For light microscopy, the sections
were visualised using diaminobenzidine (DAB) precipitation and/
or BCIP/NBT AP reaction, in a Leica CTR 5000 microscope, coupled
to a Leica DFC300FX microscope camera. After immunofluores-
cence labelling, nuclei were visualised by DAPI staining and the
sections were mounted with Mowiol/DABCO (Sigma–Aldrich)
mixture. The sections were visualised on a Leica TCS-SP5 confocal
system, coupled to a Leica CTR6500 microscope.
2.4. Tracing of hippocampal neurogenesis with c-retroviral vectors
The delivery of Eco-SFFV mCherry c-retroviral vectors was used
to trace hippocampal neurogenesis in NBH or ME7 macgreen mice
treated with GW2580 or vehicle. Viral vector design and
production was performed as previously described (Gomez-
Nicola et al., 2014a). At 14 weeks post-induction, mice were anaes-
thetised with a ketamine/rompun mixture (85 and 13 mg/kg), and
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taxically and bilaterally in the dentate gyrus (hilus) of the hip-
pocampus at each of the following coordinates from bregma:
anteroposterior, 2.0 mm; lateral, ±1.3 mm; depth, 2 mm and
anteroposterior, 1.5 mm; lateral, ±0.8 mm; depth, 2 mm.
Mouse perfusion, tissue processing and analysis were
performed as previously described, at 18 weeks post-induction
(4 weeks post tracing) (Gomez-Nicola et al., 2014a, 2014c). Coronal
sections were cut with a vibrating microtome from
paraformaldehyde-fixed brains (50 lm). After repeated rinses with
PBS, and counterstaining with DAPI (Sigma–Aldrich), free-floating
sections were mounted onto glass slides and coverslipped with a
Mowiol/DABCO (Sigma–Aldrich) mixture. Sections were visualised
on a Leica TCS-SP5 confocal system, coupled to a Leica CTR6500
microscope. Confocal stacks were acquired using 1 lm Z steps to
cover the whole morphology of the labelled cells and their
processes. Cells within the dorsal and ventral blade of the dorsal
dentate gyrus were analysed in this study.
Sholl analysis and dendrite morphometric analysis was per-
formed on 3D reconstructions of confocal Z-stacks of mCherry-
traced newborn neurons (Gomez-Nicola et al., 2014c; Sholl,
1953). Briefly, the number of crossings for concentric circles of
given radii centred at the tree stem (Sholl number) was calculated.
Starting radius and radius step size were set each at 10 lm up to
300 lm. All quantifications were performed with the help of the
image analysis software ImageJ, additionally using NeuronJ and
Sholl Analysis plug-ins.
2.5. Candidate gene expression screening
To pinpoint potential microglia-derived molecular candidates
regulating hippocampal neurogenesis in prion disease, we per-
formed a selection strategy using available expression databases
and qPCR analysis. First, a literature review was performed to
select the most important molecular pathways previously reported
to link inflammation with neurogenesis. For these pathways, we
shortlisted the main molecular mediators defining the pathway
function to progress in the screening (Sup File1). A list of 29 candi-
date genes were identified and their mRNA expression levels
checked in the ‘Prion Disease Database (Gehlenborg et al., 2009;
Hwang et al., 2009), a microarray database providing mRNA
expression data of whole brain homogenates in prion disease,
and a microarray database previously published by our group, from
hippocampal samples of ME7 and NHB mice (Lunnon et al., 2011).
Genes showing significant and consistent change were further
analysed by qPCR in samples microdissected from the dentate
gyrus (Gomez-Nicola et al., 2014c) (NBH and ME7; 12 and
20 weeks post-induction) to determine if their alterations were
specific to the neurogenic niche and their time-course. Fresh frozen
brain sections were cut with a cryostat, to then dissect the DG area
of the hippocampus, under a dissecting microscope. Samples were
homogenised in Trizol reagent (Invitrogen), following the manu-
facturer instructions to isolate RNA, as previously described
(Gomez-Nicola et al., 2014b). The isolated RNA was quantified
(Nanodrop, Thermo Scientific) and retro-transcribed to cDNA with
the iScript RT kit (Bio-Rad), after checking its integrity by elec-
trophoresis in a 2% agarose gel. cDNA libraries were analyzed by
RT-PCR using the iTaqTM Universal SYBR Green supermix (Bio-
Rad) and the custom designed gene-specific primers (Sigma–
Aldrich; Sup File2). The amplification of DNA was detected by
SYBRgreen fluorescence. Quality of the primers and the PCR
reaction were evaluated by electrophoresis in a 1.5% agarose gel,
checking the PCR product size. Data were analyzed using the DDCt
method with Primer Opticon 3 software, using GAPDH as a house-
keeping gene.Genes showing significant up- or down-regulation in ME7 com-
pared to NBH were shortlisted for the last screen, completed in DG
microdissected samples from NBH, ME7+vehicle and ME7
+GW2580 mice, in order to evaluate the effect of the microglial
component on the expression of these candidate regulators of
neurogenesis, as GW2580 has proven efficacy in selectively
inhibiting microglial proliferation and activation in prion disease
(Gomez-Nicola et al., 2013). qPCR analysis was completed as
described above, in order to identify mediators showing a expres-
sion change coincident with the change observed in neurogenesis
when treating with GW2580 (number of DCX+ cells).2.6. Gene targeting of TGFb expression
We used adenoviral vectors to target the activity of TGFb, by
driving the overexpression of Decorin, a natural inhibitor of TGFb,
as detailed before (Boche et al., 2006). Briefly, the AdDcn aden-
ovirus expressing human decorin cDNA and the AdDL70-3 aden-
ovirus (control) were used to inhibit TGFb and as an inactive
control, respectively. NBH or ME7 mice underwent bilateral
intra-hippocampal injections with 1 ll of 105 pfu/ll of adenoviral
solution 13 weeks after post-disease induction. The animals were
sacrificed 12 days after adenoviral injection and the tissues were
prepared for immunohistochemistry and RNA isolation, as detailed
above. Details on the design of the adenoviral constructs can be
found in Bett et al., 1994. The effectiveness of the AdDcn in inhibit-
ing TGFb production is documented in the literature (Al Haj Zen
et al., 2003; Zhao et al., 1999). TGFb expression levels were anal-
ysed in animals treated with AdDcn or AdDL70-3 adenovirus.
Formalin-fixed paraffin wax embedded hippocampi were dissected
and RNA isolation was performed with the ‘’RecoverAllTM Total
Nucleic Acid Isolation Kit for FFPE (Life technologies). Reverse tran-
scription and RT-PCR analysis was performed as described above.2.7. Quantification and image analysis
The quantification of antigen positive cells was performed in
DG, SGL (subgranular layer), hilus or ML (molecular layer) (n = 4
fields/mouse, n = 4–6 mice/group) after DAB immunohistochem-
istry. Data were represented as number of positive cells/mm2. To
investigate microglial density surrounding DCX+ clusters, areas
with low (0–2 adjacent DCX+ cells) or high (2 or more adjacent
DCX+ positive cells) density of immature neurons were identified
and the number of Iba1+ cells/mm2 was calculated within them.
For co-localisation studies, the total number of Iba1+ cells/mm2
and the number of Iba1+/TGFb+ cells/mm2 were quantified to
obtain a percentage of co-localisation. All quantifications were per-
formed with the help of the image analysis software ImageJ.2.8. Statistical analysis
Data were expressed as mean ± SEM and analysed with the
GraphPad Prism 5 software package (GraphPad Software). For all
data sets, normality and homoscedasticity assumptions were
reached, validating the application of the one-way or two-way
ANOVA, followed by the Tukey post-hoc test for multiple compar-
isons. The within-subjects variable used was brain region. The
between-subjects variables used were: disease (NBH vs. ME7)
and treatment. Differences were considered significant for p < 0.05.
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3.1. Microglia cells expand homogeneously at the different layers of the
dentate gyrus during prion disease
Following the recent observation of microglial proliferation in
the dentate gyrus (DG) of prion diseased mice (Gomez-Nicola
et al., 2014c), we studied the sub-regional microglial expansion
in the different layers of the DG in the ME7 model of prion disease,
to determine whether the dynamics of the microglial population
was locally associated with the neurogenic niche (subgranular
layer; SGL) (Fig. 1). We quantified the density of microglia in the
hilus, SGL, granular layer (GL) and molecular layer (Mol) of the
DG in ME7 mice compared with NBH controls, and observed signif-
icant increases in all the sub-regions analysed (Fig. 1A, B). We cal-
culated the percentage distribution throughout the layers, to test
whether microglia were expanding preferentially in some sub-
regions, and found no significant change in microglial percentage
distribution between ME7 and NBH mice (Fig. 1C). These results
support a homogeneous expansion in the microglial population
in the DG during ME7.
We further tested the hypothesis of a localised cell-contact
interaction of microglial cells with neural progenitor cells (NPCs;
DCX+) in the ME7 model. We previously reported that DCX+ cells
form high density clusters in this model (Gomez-Nicola et al.,
2014c), so we analysed if microglial numbers correlate with the
expansion of DCX+ cells, grouped as high- or low-density clusters
(Fig. 1D, E). The increased density of DCX+ cells correlated with
the increased density of microglial cells, being this association
equal in both ME7 and NBH mice (1.3 fold increase) (Fig. 1D, E).
Our results show that, although the microglial population
expands in the DG of prion diseased mice, there is no clear physical
association with the neurogenic niche, suggesting that a potential
neuromodulatory action of microglia shall be mediated through
diffusible factors.3.2. The inhibition of microglial proliferation during prion disease
reveals a pro-neurogenic activity of microglia
To investigate the potential regulatory activity of microglia on
neurogenesis, we took advantage of their dependence on CSF1R
signalling in the control of the expansion of this population
(Gomez-Nicola et al., 2013). Thus, by either over-activating or
inhibiting the activity of this receptor we can control microglial
numbers in ME7 mice and analyse possible downstream effects
of microglia on neurogenesis. We have taken advantage of the fact
that the expression of EGFP in macgreen mice is driven by the
CSF1R promoter (c-fms), making it an optimal reporter mouse for
analysing the specificity of CSF1R expression (Sasmono et al.,
2003). Using immunofluorescence and confocal microscopy we
found no evidence of expression of CSF1R in neurons (NeuN+;
Fig. 2A), astrocytes (GFAP+; Fig. 2A) or NPCs (DCX+; Fig. 2B), sup-
porting that CSF1R expression is exclusive of microglia (Erblich
et al., 2011; Gomez-Nicola et al., 2013; Sasmono et al., 2003).
We delivered intracerebral recombinant CSF1 or IL34, ligands
for CSFR1, to the hippocampus of prion diseased mice (Fig. 3A) in
order to increase microglial proliferation (Gomez-Nicola et al.,
2013), and analysed the effects on the number of NPCs (DCX+).
The increased number of microglia, driven by the activity of both
CSF1 and IL34 (Gomez-Nicola et al., 2013), led to an increase in
the number of DCX+ in the DG (Fig. 3B), suggesting a positive cor-
relation between microglial expansion and neurogenesis. We fur-
ther investigated this correlation and examined the effects of the
inhibition of microglial proliferation by the selective blockade of
the tyrosine kinase activity of CSF1R by GW2580 (Gomez-Nicolaet al., 2013) in macgreen mice with prion disease (ME7) or NBH
controls (Fig. 3A). Oral dosing with GW2580 prevented the ampli-
fication of the microglial population in prion disease (Fig. 4), as
previously reported (Gomez-Nicola et al., 2013). The analysis of
cell proliferation at the neurogenic niche (SGL) showed a signifi-
cant increase in BrdU+ cells in ME7 mice when compared to NBH
controls, which was prevented by GW2580 (Fig. 2D), consistent
with previously reported data (Gomez-Nicola et al., 2014c). The
expansion of DCX+NPCs observed in ME7 mice was prevented
when microglial proliferation was blocked (Fig. 3C, E), providing
evidence that the role of microglia during prion disease was mainly
pro-neurogenic.
The observed changes in neurogenic activity upon inhibition of
microglial proliferation led us to analyse later stages of the neuro-
genic cascade. After dosing NBH and ME7 animals with GW2580
we traced newborn neurons with c-retroviral vectors expressing
mCherry, and analysed neuronal differentiation and integration
4 weeks later (Fig. 3A). We observed the characteristic neuronal
phenotype in prion diseased granule cells (Gomez-Nicola et al.,
2014c): Sholl analysis of the dendritic trees revealed the shorter,
hyper-ramified and tortuous dendritic trees of ME7 neurons when
compared with NBH neurons (Fig. 3F, G, H). The inhibition of
microglial proliferation prevented the defective ramification of
granule cells observed in ME7 mice, the granule cells now appear
to have morphological parameters similar to those seen in NBH
controls (Fig. 3F, G, H).
Our results demonstrate the pro-neurogenic activity of micro-
glia during prion disease, as the inhibition of their proliferation
restores baseline levels of neurogenesis. Associated with the reduc-
tion in neurogenesis was the notable restoration of a correct neu-
ronal differentiation and a normal dendritic morphology.3.3. Gene expression screening identifies TGFb as a key regulator of the
microglial-dependent pro-neurogenic activity in prion disease
We next set out to identify the molecular determinants of the
pro-neurogenic actions of microglia in prion disease and designed
a progressive screening of gene expression profiles (see methods).
We started by analysing the expression levels of microglia related
mRNA species reported in two published microarray studies of
models of prion disease, using whole brain (Gehlenborg et al.,
2009) or hippocampal samples (Lunnon et al., 2011). From a start-
ing list of 28 genes representing the main pathways controlling
hippocampal neurogenesis with some link to inflammation (Sup
File1), we defined a total of 20 genes to progress to the next step
of the screening, selecting those with a clear and consistent trend
in the expression profiles (Fig. 5A). The mRNA expression of the
20 candidate genes was analysed by RT-PCR in dentate gyrus
microdissected samples from both NBH and ME7 mice, at 12 and
20 weeks post-induction. RT-PCR analysis highlighted 8 candidate
genes (Patched, Shh, Bmp4, Bmp1r, Tgfb1, Cntf, Igf1, Vegfa) with sig-
nificant expression alterations in the dentate gyrus of ME7 mice,
when comparison to NBH mice (Fig. 5A). The 8 shortlisted genes
were analysed in samples from microdissected dentate gyrus
NBH, ME7 and ME7+GW2580mice, in order to pinpoint those asso-
ciated with microglial cells, as treatment with GW2580 has been
shown effective in arresting the amplification of the microglial
population in prion disease(Gomez-Nicola et al., 2013). The
changes in relative expression of Tgfb1, Cntf, Igf1 and Bmp4 fol-
lowed the same directions previously observed for the number of
DCX+ cells in ME7 mice and ME7 mice in response to GW2580
(Fig. 2E), upregulated in ME7 mice and downregulated when
microglial proliferation was blocked (Fig. 5B). These changes sug-
gested that Tgfb1, Cntf, Igf1 and Bmp4 were likely candidate genes
driving the pro-neurogenic actions of microglia in prion disease.
Fig. 1. Increased microglisis in the dentate gyrus of prion-diseased mice. (A–C) Quantification of the density (B) or relative sub-regional distribution (C) of microglial cells
(Iba1+) in the dentate gyrus (DG) of prion-diseased mice (ME7; black bars) or NBH controls (normal brain homogenate, open bars). Representative images from c-fms EGFP
NBH and ME7 mice shown in A (nuclei shown in red, DAPI). (B) Quantified data expressed as mean ± SEM of the number of Iba1+ cells/mm2. (C) Quantified data expressed as
mean ± SEM of the % of Iba1+ cells at a specific layer from the total population of Iba1+ at the dentate gyrus (DG). (D, E) Analysis of the cell-contact interaction of microglial
cells (Iba1+) with neural progenitor cells (NPCs, DCX+) at the DG of ME7 or NBH mice. Microglial density was measured at high- or low-density DCX+ clusters. (E) Quantified
data expressed as mean ± SEM of the number of Iba1+ cells/mm2 at high/low density DCX+ clusters. Statistical differences: *p < 0.05 (vs. matching NBH area), ***p < 0.001 (vs.
matching NBH area). Data were analysed with a two-way ANOVA, showing statistical comparisons arising from a post-hoc Tukey test (n = 4–6). Scale bar in (A, D) 100 lm.
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actions of this cytokine are key for the function of microglia in
health and disease (Boche et al., 2006; Gomez-Nicola and Perry,
2014a, 2014b). First, we confirmed TGFb expression by microglia
(Iba1+) in ME7 mice by immunostaining (Fig. 6A); we found that
a consistent proportion of microglia co-localised with TGFb in both
NBH (61.27%) and ME7 (61.21%) hippocampi (Fig. 6A). To investi-
gate whether TGFb was the major mediator in the pro-
neurogenic actions of microglia, we inhibited the activity of TGFb
by the adenoviral expression of Decorin, a natural inhibitor of TGFb
(Boche et al., 2006). We observed a reduction in TGFb1 mRNA
expression levels in response to the Decorin adenovirus (AdDcn),
both in NBH and ME7 mice, when compared with mice injected
with a control adenovirus (AdDL70-3) (Fig. 6B). We then analysed
the effects of TGFb inhibition on hippocampal neurogenesis, using
the number of DCX+ cells as a readout. The inhibition of the activity
of TGFb by AdDcn blocked the disease related expansion of DCX+
cells observed in ME7 mice (Fig. 6C). This pro-neurogenic effect
of TGFb in prion disease was also observed (not significant) inNBH mice (Fig. 6C), suggesting a TGFb -dependent control of base-
line neurogenesis. The results observed by the inhibition of TGFb
activity mimicked those observed when preventing the amplifica-
tion of the microglial population in prion disease, suggesting that
TGFb is a pivotal link between inflammation and neurogenesis.4. Discussion
The study of the impact of neuroinflammation on the regulation
of adult neurogenesis is of crucial relevance to understand the
potential mechanisms of repair in neurodegenerative diseases.
Several chronic neurodegenerative diseases are characterised by
a profound innate immune response (Gomez-Nicola and Perry,
2014a, 2014b), and aberrant modifications of the neurogenic
reserve (Gomez-Nicola et al., 2014c; Miller and Gomez-Nicola,
2014), although how these two processes interact is not yet fully
understood. By selectively controlling the microglial number dur-
ing prion disease, we provide evidence for a pro-neurogenic role
Fig. 2. CSF1R is not expressed by neurons, astrocytes or NPCs. (A) Immunohistochemical analysis, coupled to confocal microscopy, of the localisation of EGFP (driven by the c-
fms (CSF1R) promoter in macgreen mice) in astrocytes (GFAP+, blue) or neurons (NeuN+, red) in the hippocampus of ME7 mice. (B) Immunohistochemical analysis, coupled to
confocal microscopy, of the localisation of EGFP (driven by the c-fms (CSF1R) promoter in macgreen mice) in neural progenitor cells (NPCs, DCX+; red) at the dentate gyrus
(DG) of ME7 mice. Nuclei are stained in blue. Scale bar in (A, B) 50 lm.
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blocked microglial proliferation for 4 weeks using the CSF1R tyro-
sine kinase inhibitor (GW2580), and demonstrated a reduction in
neurogenesis that supports the hypothesis that microglia have a
net pro-neurogenic effect during prion disease. These results were
corroborated by a gain-of-function experiment, delivering recom-
binant CSF1 or IL34 and observing the opposite effects namely an
increase in neurogenesis. Although a report recently suggested
CSF1R is expressed and functions in neurons (Luo et al., 2013),
we observed that CSF1R-modulatory approaches are specific for
microglia, and found no evidence that the receptor is expressed
either by neurons or astrocytes, supporting previously reported
data (Erblich et al., 2011; Gomez-Nicola et al., 2013; Sasmono
et al., 2003).
The present data progress recently published data from our
group, reporting an increase in neurogenesis during prion disease
that counteracts the extensive neuronal loss in the dentate gyrus
(Gomez-Nicola et al., 2014c). However, the neurons newly gener-
ated during prion disease fail to develop a normal differentiation
pattern and to regenerate morphology or electrophysiological
properties of the lost granule cells, supporting the hypothesis thatalthough prion disease induces a compensatory self-repairing
mechanism this fails to restore the lost functions (Gomez-Nicola
et al., 2014c; Miller and Gomez-Nicola, 2014). We have demon-
strated that some factors derived from microglia contribute to
the aberrant increase in neurogenesis, and also play a role in the
abnormal development and differentiation of newborn neurons
as evidenced by the restoration of a normal differentiation pro-
gram when microglial proliferation was inhibited. Although micro-
glia would unlikely determine all the biology of NSCs in this model,
these complementary actions of microglia suggest that the phar-
macological strategies targeting microglial proliferation in chronic
neurodegeneration could be beneficial to prevent the aberrant
neurogenic events observed not only in prion disease, but also in
other chronic neurodegenerative diseases (Gomez-Nicola et al.,
2014c; Li et al., 2009; Llorens-Martin et al., 2013; Sun et al., 2009).
Previous studies are in line with our findings as they show the
important contribution of microglia for the maintenance and sup-
port of hippocampal neurogenesis in the steady state and during
pathological events (Butovsky et al., 2006; Ekdahl et al., 2009;
Ziv et al., 2006). For example, microglia can have a stimulating
effect by providing soluble factors essential for neurogenesis
Fig. 3. The gain- or loss-of-activity of CSF1R reveals a pro-neurogenic role of microglia in prion disease. (A) Gain of activity of CSF1R was achieved by the intrahippocampal
administration of recombinant CSF1, IL34 or vehicle in ME7 mice, while loss of activity of CSF1R achieved by the prolonged oral dosing of GW2580, as previously described
(Gomez-Nicola et al., 2013). (B) Analysis of the density of neural progenitor cells (NPCs; DCX+) at the subgranular layer (SGL) of the dentate gyrus (DG) after gain of activity of
CSF1R in prion-diseased mice (+CSF1 or +IL34). Quantified data expressed as mean ± SEM of the number of DCX+ cells/mm2. (C–E) Analysis of the density of proliferating cells
(BrdU+; D) and NPCs (DCX+; E) at the SGL of the DG after loss of activity of CSF1R in prion-diseased mice (+GW2580). Quantified data expressed as mean ± SEM of the number
of BrdU+ or DCX+ cells/mm2. Representative images shown in C. (F–H) Fluorescent marking of neuron generation in the DG by the intraparenchymal (hilus) administration of
ecotropic SFFV c-retroviral (Eco-SFFV-RV) vectors driving the expression of mCherry, in ME7 or NBH mice, treated with GW2580 or control (see A). (F) Projection of confocal
Z-stacks of mCherry+ 4-weeks old granule neurons from NBH (normal brain homogenate) or ME7 mice (see A). The maturation of the dendritic trees was analysed according
to the Sholl method (G), representing the mean ± SEM of the number of intersections at increasing distances from the cell soma. (H) Quantification of the maximum distance
from cell soma (lm) or the total number of dendrites/neuron, in cells traced as described previously, expressed as mean ± SEM. For G, statistical differences: *p < 0.05 ME7
control vs. NBH control, #p < 0.05 ME7 control vs. ME7+GW2580. Data were analysed with a T-test. For B, statistical differences: *p < 0.05 (vs. ME7+Sal). For D, E, H, statistical
differences for connected bars: *p < 0.05, **p < 0.01. Data were analysed with a one-way (B) or two-way (D, E, H) ANOVA showing statistical comparisons arising from a post-
hoc Tukey test (n = 4–6). Scale bar in (C) 100 lm, (F) 50 lm.
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Fig. 4. GW2580 inhibits the proliferation of microglial cells in ME7 mice. Analysis of the impact of the long-term treatment (4 weeks) of NBH (normal brain homogenate) or
ME7 mice with control or GW2580, on the number of microglial cells. Representative pictures from the DG, with microglial cells identified by the expression of EGFP
(macgreen mice; green). Scale bar 200 lm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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support the hypothesis that microglial expansion is detrimental
for hippocampal adult neurogenesis (Kempermann and
Neumann, 2003). Monje et al. reported a decrease in neurogenesis
in vitro when precursor cells were exposed to a conditioned med-
ium from activated microglia (Monje et al., 2003). Ekdahl et al.
demonstrated that LPS-induced microglia alters neurogenesis and
that suppression of the microglial response by minocycline, an
anti-inflammatory drug, restores the neurogenic activity of the
hippocampus that was impaired by inflammatory processes
(Ekdahl et al., 2003). Further research supports the idea that
whether the effect of activated microglia in the injured CNS is pos-
itive or negative is determined by the microenvironment changes
which tightly regulate the state of activation and the functional
phenotype of microglia (Butovsky et al., 2006; Gomez-Nicola and
Perry, 2014b). More importantly, recent studies reported that a
dampened microglial response during chronic unpredictable stress
caused a decline in neurogenesis, which restored after the stimula-
tion of microglial proliferation by CSF1 (Kreisel et al., 2014).
The cytokine profile of prion disease is dominated by high levels
of TGFb suggesting a key role of this cytokine in neurodegenerative
disorders (Boche et al., 2006). TGFb is known to act as an anti-
inflammatory and neuroprotective agent (Flanders et al., 1998).In this study, using a screening of potential microglial-derived
modulators of neurogenesis, we highlight the relevance of TGFb
in controlling the aberrant pro-neurogenic activity observed in
prion disease. We modulated TGFb activity using an adenovirus
to deliver a natural inhibitor of TGFb, Decorin (AdDcn), and provide
mechanistic evidence for the pro-neurogenic role of TGFb. A previ-
ous study demonstrated an increase of TGFb expression through-
out the progression of prion disease, which coincides with the
progressive enhanced microglial activation observed during this
time course (Boche et al., 2006). The parallel evolution of these
two features suggests a strong link between microglia and TGFb
during prion disease, evidenced now by our data resulting from
the inhibition of microglial proliferation. In addition to the
reported effects of microglial proliferation on neurogenesis in
prion diseased mice, we noted a trend supporting a TGFb-
dependent pro-neurogenic effect of microglia in control mice.
NBH mice show the same balance of microglia/DCX+ cells com-
pared to ME7 mice and the same proportion of the population
express TGFb as ME7 mice, suggesting a similar regulatory system
being in place for controlling neurogenesis in a TGFb-dependent
manner. One key factor limiting the impact of the
anti-proliferative strategies on NBH mice is the very low rate of
proliferation of microglia in the normal brain (Lawson et al.,
Fig. 5. Gene expression screening of potential molecules regulating the pro-neurogenic activity of microglia in prion-diseased mice. (A) Progressive screening of gene
expression profiles (see methods and Table S1), from microglia related mRNA species reported in two published microarray studies of models of prion disease, using whole
brain (Gehlenborg et al., 2009) or hippocampal samples(Lunnon et al., 2011) and RT-PCR analysis in the dentate gyrus (DG) microdissected samples from both NBH (normal
brain homogenate) and ME7 mice, at 12 and 20 weeks post-induction. Data shown colour-coding (blue to red) fold-change of prion vs. control from 9.61 to +12.81. (B) The
mRNA expression of shortlisted molecular candidates (Patched, Shh, Bmp4, Bmp1r, Tgfb1, Cntf, Igf1, Vegfa) was analysed by RT-PCR in DG microdissected samples from NBH,
ME7 and ME7+GW2580 mice. Expression of mRNA represented as mean ± SEM and indicated as relative expression compared to the housekeeping gene (GAPDH) using the
2DDCT method. Statistical differences for connected bars: *p < 0.05, **p < 0.01, ***p < 0.001. Data were analysed with a one-way ANOVA showing statistical comparisons arising
from a post-hoc Tukey test (n = 4).
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Fig. 6. TGFb is responsible for the microglial pro-neurogenic activity in prion disease. (A) Immunohistochemical analysis of the localisation of TGFb (brown) in microglial cells
(Iba1+, blue) in ME7 mice. Representative examples of double-positive cells are indicated by arrowheads. (B) TGFbmRNA expression analysed by RT-PCR in the hippocampus
of NBH+AdDL70-3, NBH+AdDcn, ME7+AdDL70-3 or ME7+AdDcn mice. Expression of mRNA represented as mean ± SEM and indicated as relative expression compared to the
housekeeping gene (GAPDH) using the 2DDCT method. (C) Analysis of the density of neural progenitor cells (NPCs; DCX+) at the subgranular layer (SGL) of the dentate gyrus
(DG) in NBH+AdDL70-3, NBH+AdDcn, ME7+AdDL70-3 or ME7+AdDcn mice. Quantified data expressed as mean ± SEM of the number of DCX+ cells/mm2. Scale bar in (A)
50 lm. Statistical differences for connected bars: *p < 0.05. Data were analysed with a two-way ANOVA showing statistical comparisons arising from a post-hoc Tukey test
(n = 4–6).
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and long-term usage of CSF1R inhibitors in normal mice would
provide a useful approach to study the role of microglia in
neurogenesis in the normal healthy brain.
The observation that TGFb has pro-neurogenic actions in the
healthy and diseased neurogenic niche would be consistent with
recently reported data on ALK5 (TGFb Receptor I), which suggests
that the activation of TGFb signaling has proneurogenic functions
in the healthy hippocampal neurogenic niche (He et al., 2014), as
suggested by previous studies (Battista et al., 2006; Mathieu
et al., 2010). However, TGFb functions in the neurogenic niche
are a subject of controversy. TGFb has been shown to induce a neg-
ative feedback regulation in controlling the NSCs pool (Wachs
et al., 2006). The apparent controversy between these studies
and our data could be explained by a context-dependent (healthy
brain vs. diseased, hippocampus vs. subventricular zone) mode of
action of TGFb, as well as cell-dependent functions as evidencedhere by the microglia-derived TGFb. For example, serum-derived
factors are able to determine the effect of TGFb on the neurogenic
niche (Kane et al., 1996; Wachs et al., 2006). Activated microglia
have been identified as one of the cells that contributes to TGFb
production, with microglial TGFb expression increased in response
to cerebral ischemia and leading to enhanced neuronal survival
(Flanders et al., 1998). In addition, TGFb inhibits macrophage func-
tion by regulating the production of pro-inflammatory cytokines,
effect potentiated when cooperating with CSF1, suggesting a
strong interaction of microglial proliferation and TGFb signaling
(Lodge and Sriram, 1996). These ideas suggest that a more targeted
analysis of the interaction of TGFb with different cells is needed, in
order to better understand the multiple roles of this cytokine
in vivo.
Our gene screening strategy highlighted other microglia-
derived molecules potentially regulating hippocampal neurogene-
sis. We found changes in the BMP pathway that could explain the
C. De Lucia et al. / Brain, Behavior, and Immunity 55 (2016) 179–190 189progressive decrease in hippocampal neurogenesis previously
reported in prion diseased mice (Gomez-Nicola et al., 2014c). The
role of the BMP pathway in adult neurogenesis has not been fully
determined, however, there is evidence to suggest a role in driving
NSCs to quiescence. The activation of BMPR1A determines the rate
of neurogenesis and prevents NSCs pool depletion, a system that
can be inhibited by Noggin (Mira et al., 2010). This hypothesis is
supported by our results that show an increase in BMP4 and
BMP1RA mRNA, as well as a decrease in Noggin mRNA, during
the disease. The observed inhibition of this pathway correlates
with the late decline in neurogenesis observed in ME7 mice, after
a pro-neurogenic surge that extends until mid-late phases of the
model (Gomez-Nicola et al., 2014c). This suggests that BMP4 may
be a microglial-derived factor, while BMP1RA is not, consistent
with previously reported findings on this receptor (Mira et al.,
2010). While BMP4 expression has been reported in oligodendro-
cytes and astrocytes (Sabo et al., 2011), no studies have been direc-
ted to determine its functions in microglia.
The observed expression trends of CNTF and IGF1 may also be of
interest when considering microglia-derived factors regulating
hippocampal neurogenesis. Both molecules have roles in providing
neurotrophic support to nascent neurons (Aberg et al., 2000;
Sendtner et al., 1994). CNTF is responsible for regulating the size
of the NSCs pool and their differentiation. Experiments with
CNTF-/- mice and anti-CNTF antibodies showed reductions in pro-
liferation and number of NSCs and newborn neurons (Muller
et al., 2009) whereas CNTF infusion in the forebrain increased them
(Bath and Lee, 2010), thereby suggesting an essential role in main-
taining neurogenic activity. Our results emphasise these findings
and provide new evidence of its role during disease; an increase
in CNTF during the late stage of ME7 may be a way of opposing
the ongoing neurodegeneration by providing trophic support to
forming neurons. Although this mechanism appears to be
microglia-dependent, CNTF expression has been reported so far
only in Schwann cells and astrocytes (Ekdahl et al., 2003) and its
expression and activity in microglia still needs to be studied. A
similar trend is observed for IGF1 expression, which is upregulated
in prion disease and appears to be microglia associated. Circulating
IGF1 has neurotrophic and neurogenic functions (Aberg et al.,
2000; Trejo et al., 2001) and the neuroprotective actions of IGF1
are key for chronic neurodegenerative diseases (Carro et al.,
2002), suggesting a link between microglia and IGF1 expression.
In summary, by taking advantage of the selective targeting of
microglial proliferation, we have uncovered a pro-neurogenic role
for microglia in chronic neurodegeneration. Microglia exert this
pro-neurogenic role as least in part through TGFb, linking a key
neuroinflammatory pathway with the intrinsic self-repairing
potential of the brain, which opens new avenues for the design
of neuroprotective and restorative approaches.Competing financial interests
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